Core Viewpoint - The approval of non-naloxone by the National Medical Products Administration of China marks a significant milestone for the company, as it becomes the second domestic enterprise to receive such approval for this active pharmaceutical ingredient [1] Group 1: Company Developments - The company has received approval for non-naloxone to be used as an active pharmaceutical ingredient in marketed formulations [1] - Non-naloxone is primarily indicated for adult patients with chronic kidney disease associated with type 2 diabetes [1] Group 2: Product Significance - The drug is designed to reduce the risk of a sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular mortality, and hospitalization due to heart failure [1]
石四药集团(02005.HK)非奈利酮获批准登记为上市制剂使用原料药